Abstract
Purpose :
To assess the prognosis of nAMD with hemorragic choroidal neovascularization treated with ranibizumab, bevacizumab and aflibercept
Methods :
We investigated twelve nonconsecutive cases of nAMD with predominantely hemorragic neovascularization over the course of six years. During the investigation, we looked for signs of worsening or improvement in patient’s vision and for difference between the chose drugs results
Results :
During the treatment, we found a satisfatory response of the eyes suffering from nAMD with hemorragic choroidal neovascularization when treated with anti VEGF drugs. The first signs of improvement were noticed three months following the initial therapy and the patient who took the longest to show improvement after the begining of the treatment did so after eight months. No patient showed imediate response to the treatment and no difference between the drugs were noticed during the treatment.
Conclusions :
These cases of nAMD with hemorragic choroidal neovascularization benefited from the treatment with anti VEGF, despite its first responses being held after three months of treatment. No difference in the result between drugs was noticed. 70% of the eyes treated showed improvement in the visual acuity. Two of the cases evolved to subretinal fibrosis. nAMD is still an important therapy in patients of nAMD
This is a 2021 ARVO Annual Meeting abstract.